⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131482 | 0.62 | — | — | |
| SCHEMBL3151003 | 0.59 | — | — | |
| SCHEMBL156285 | 0.59 | — | — | |
| SCHEMBL6087934 | 0.58 | — | — | |
| SCHEMBL1378685 | 0.57 | PIK3CG (0.46) | — | |
| SCHEMBL367524 | 0.56 | CDC25B (0.39) | — | |
| SCHEMBL1180 | 0.56 | CDC25B (0.39) | — | |
| SCHEMBL29590064 | 0.56 | CDC25B (0.39) | — | |
| SCHEMBL29965655 | 0.56 | CDC25B (0.39) | — | |
| SCHEMBL6541862 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6057346-A | USED TO DELAY OR SUPPRESS THE TRANSITION OF A RETROVIRAL INFECTION FROM A LATENT TO A VIRULENT CONDITION, THEREBY AMELIORATING RETROVIRALLY CAUSED DISEASES SUCH AS AIDS, ARE ALSO USEFUL IN CANCER TREATMENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-05-02 | — | — | US | claimed |
| US-5880129-A | ADMINISTERING ANTIPROLIFERATIVE, ANTIINVASIVE, ANTIMETASTASIS AMOUNT OF SELECTED SIGNAL TRANSDUCTION INHIBITOR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-03-09 | — | — | US | claimed |
| US-5602156-A | ADMINISTERING IN TREATMENT FOR NERVE DISORDERS, ARTHRITIS, ALZHEIMER'S DISEASE, WOUND HEALING, CORNEAL ULCERS AND FERTILITY PROBLEMS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-11 | — | — | US | claimed |
| US-5405782-A | Reverse phase liquid chromatography | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-04-11 | — | — | US | claimed |
| EP-0644880-A1 | 1,2,3-TRIAZOLE AND IMIDAZOLE COMPOUNDS AND THEIR ANTITUMOR USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-03-29 | — | — | EP | claimed |
| WO-1995007695-A1 | METHOD FOR INHIBITING METALLOPROTEINASE EXPRESSION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-03-23 | — | — | WO | claimed |
| WO-1994023293-A1 | A DETECTION AND QUANTITATION METHOD FOR THERAPEUTIC AGENTS IN BLOOD | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-10-13 | — | — | WO | claimed |
| WO-1993025536-A1 | 1,2,3-TRIAZOLE AND IMIDAZOLE COMPOUNDS AND THEIR ANTITUMOR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-12-23 | — | — | WO | claimed |
| EP-2660241-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2651916-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-6790936-B1 | CARBOXYAMIDO-TRIAZOLE (CAI); SH DOMAINS; FOR USE IN CANCER THERAPY; DRUG SCREENING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-09-14 | — | — | US | disclosed |
| WO-1995008327-A1 | METHOD FOR INHIBITING ANGIOGENESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-03-30 | — | — | WO | disclosed |
| EP-0644880-A1 | 1,2,3-TRIAZOLE AND IMIDAZOLE COMPOUNDS AND THEIR ANTITUMOR USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-03-29 | — | — | EP | disclosed |
| WO-1995007695-A1 | METHOD FOR INHIBITING METALLOPROTEINASE EXPRESSION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-03-23 | — | — | WO | disclosed |
| US-5359078-A | Interrupts the signalling pathways required for proliferation and metastasis of cancer cells | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994023293-A1 | A DETECTION AND QUANTITATION METHOD FOR THERAPEUTIC AGENTS IN BLOOD | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1993025536-A1 | 1,2,3-TRIAZOLE AND IMIDAZOLE COMPOUNDS AND THEIR ANTITUMOR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-12-23 | — | — | WO | disclosed |